Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Developing Guidance On Rational Development Of Combined Novel Drugs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

 

You may also be interested in...



Sponsors Caution Against Premature Expanded Access For Novel HCV Drugs

Early positive trial results for direct-acting antivirals for Hepatitis C, combined with the seriousness of the disease and unmet clinical need, make Hep C an obvious target for expanded access programs.

Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers

A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel